Re:Show HN: CatalystAlert – Free biotech catalyst calendar (...
by nykodev on Monday December 08, 2025 @01:38AM
(#46189133)
Last year I panic-sold my biotech positions after missing two PDUFA dates in the same week. Both drugs got rejected. I was using a free tracker that hadn't been updated in months.
So I looked at what's available:
→ BioPharmCatalyst: $30-50/month
→ Free alternatives: clunky UIs from 2010, outdated data, broken filters
→ Finviz/Yahoo: no catalyst-specific tracking
I built CatalystAlert to fix this.
What it tracks:
→ 985 biotech companies, 1714 drugs in pipeline
→ PDUFA dates, Phase 1/2/3 readouts, AdCom meetings
→ Data pulled daily from ClinicalTrials.gov, SEC EDGAR, FDA
Stack: Next.js, Python data pipeline, daily automated scraping.
No account required, no paywall, no "unlock premium to see this date."
The core stays free. I'm prototyping V2 with ML-based approval probability predictions (trained on historical FDA decisions + trial endpoints) – that might have a paid tier eventually, but the calendar never will.
Feedback I'd love:
1. Data sources I'm missing?
2. Filters or views that would save you time?
3. Anything broken or confusing?
So I looked at what's available:
→ BioPharmCatalyst: $30-50/month → Free alternatives: clunky UIs from 2010, outdated data, broken filters → Finviz/Yahoo: no catalyst-specific tracking
I built CatalystAlert to fix this.
What it tracks: → 985 biotech companies, 1714 drugs in pipeline → PDUFA dates, Phase 1/2/3 readouts, AdCom meetings → Data pulled daily from ClinicalTrials.gov, SEC EDGAR, FDA
Stack: Next.js, Python data pipeline, daily automated scraping.
No account required, no paywall, no "unlock premium to see this date."
The core stays free. I'm prototyping V2 with ML-based approval probability predictions (trained on historical FDA decisions + trial endpoints) – that might have a paid tier eventually, but the calendar never will.
Feedback I'd love: 1. Data sources I'm missing? 2. Filters or views that would save you time? 3. Anything broken or confusing?
Thanks for checking it out.